{"id":"W3158136113","doi":"10.1038/s41375-021-01257-7","title":"Hairy cell leukemia and COVID-19 adaptation of treatment guidelines","year":2021,"lang":"en","type":"review","venue":"Leukemia","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":46,"is_retracted":false,"has_abstract":true,"ca_institutions":"University of Manitoba; Research Institute in Oncology and Hematology; CancerCare Manitoba","funders":"Cilag; Canadian Institutes of Health Research; Kite Pharma; Genentech; Ascentage Pharma; Pharmacyclics; Agios Pharmaceuticals; Astellas Pharma; Adaptive Biotechnologies; Astex Pharmaceuticals; H. Lundbeck A/S; TG Therapeutics; Royal Marsden NHS Foundation Trust; CancerCare Manitoba Foundation; MEI Pharma; MacroGenics; Sunesis; University of Pittsburgh; AbbVie; National Cancer Institute; Servier; Gilead Sciences; Teva Pharmaceutical Industries; Celgene; Novartis; Pfizer; Biogen; AstraZeneca; Amgen; National Institutes of Health; Leukemia and Lymphoma Society of Canada; BeiGene; Hairy Cell Leukemia Research Foundation; GlaxoSmithKline","keywords":"Coronavirus disease 2019 (COVID-19); Pandemic; Medicine; Hairy cell leukemia; Immunosuppression; Intensive care medicine; Life expectancy; Leukemia; 2019-20 coronavirus outbreak; Immunology; Disease; Virology; Internal medicine; Infectious disease (medical specialty)","routes":{"ca_aff":true,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002296143,0.0005964467,0.001178015,0.002617054,0.0003379378,0.001206538,0.001431872,0.001866117,0.005085525],"category_scores_gemma":[0.00455882,0.0002544651,0.001252137,0.001956649,0.0004803041,0.001314292,0.0007942701,0.003040981,0.00251382],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001276052,"about_ca_system_score_gemma":0.003861388,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.003357644,"about_ca_topic_score_gemma":0.005605859,"domain_scores_codex":[0.9988732,0.0002849853,0.0002757651,0.0001008102,0.0003804084,0.00008478077],"domain_scores_gemma":[0.997926,0.0007659423,0.0002803026,0.00005579735,0.0008608137,0.0001111902],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.000112692,0.00006500708,0.0002336801,0.02958725,0.0001294286,0.0001508069,0.00009778328,0.0002562108,0.0005734451,0.006606919,0.2011651,0.7610217],"study_design_scores_gemma":[0.00002114886,0.00003127081,0.0004176401,0.01577626,0.0001067806,0.0003286538,0.00003353195,0.00003496962,0.0001159359,0.001304017,0.9818197,0.00001013208],"study_design_candidate":"not_applicable","study_design_consensus":null,"genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.0001480278,0.9855205,0.0003676075,0.00653092,0.00215182,0.00005804548,0.0002297583,0.00003533088,0.004957973],"genre_scores_gemma":[0.001173994,0.9900346,0.001106331,0.004373076,0.0006635244,0.00007043451,0.0005125906,0.000008943367,0.002056496],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.005085525,"threshold_uncertainty_score":0.01701277,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1891866795627362,"score_gpt":0.4336963452685132,"score_spread":0.244509665705777,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}